Zeltia, S.A. Information

In 2015, effective since October 30th, Zeltia has been absorbed in a reverse merger by PharmaMar. After the reverse merger between Zeltia and PharmaMar, the rest of the subsidiary companies formerly owned by Zeltia are fully owned by PharmaMar. Founded in 1939, since its origin Zeltia group has been involved in the biopharmaceutical and chemical. Zeltia publicly traded since 1963 and in the continuous market since 1998. On November 2nd, 2015, after completing the reverse merger, Company started trading on the BME Spanish stock exchange as PharmaMar. The Group has activities in two different sectors, the biopharmaceutical industry and consumer chemical. In the biopharmaceutical sector differ several lines of research: Oncology, molecular diagnostics and genetic identification and RNAi (RNA interference) In the field of consumer chemical there are several business lines: manufacture and sale of products for home care, manufacturing and sale of paints and protective coatings timber for professional and DIY. Believe our research and our greatest contribution to society and future. Collaborate actively in activities promoting research and disseminating knowledge through partnerships and networking with hospitals around the world, research centers and universities. Zeltia Group philosophy from Founded in 1939, is to contribute to the improvement of society through the development of drugs to treat diseases for which there is no effective remedy, such as cancer, Alzheimer's and glaucoma investigated to improve the quality of life for patients, so each year we invest more resources in R &D in order to provide innovative treatments.